Svetlana Ya Zhanaeva

Dr. Svetlana Ya Zhanaeva

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Maria A TikhonovaMaria A Tikhonova
Maria A Tikhonova
SZSvetlana Ya Zhanaeva
Svetlana Ya Zhanaeva
ASAnna A. Shvaikovskaya
Anna A. Shvaikovskaya
NONikita M. Olkov
Nikita M. Olkov
LALyubomir I. Aftanas
Lyubomir I. Aftanas
Konstantin V. DanilenkoKonstantin V. Danilenko
Konstantin V. Danilenko
Human brain state is usually estimated by brain-specific substances in peripheral tissues, but, for most analytes, a concordance between their content in the brain and periphery is unclear. In this systematic review, we summarized the investigated correlations in humans. PubMed was searched up to June 2022. We included studies measuring the same endogenous neurospecific analytes in the central nervous system and periphery in the same subjects. Not eligible were studies of cerebrospinal fluid, with significant blood–brain barrier disruption, of molecules with well-established blood-periphery concordance or measured in brain tumors. Seventeen studies were eligible. Four studies did not report on correlation and four revealed no significant correlation. Four molecules were examined twice. For BDNF, there was no correlation in both studies. For phenylalanine, glutamine, and glutamate, results were contradictory. Strong correlations were found for free tryptophan (r = 0.97) and translocator protein (r = 0.90). Thus, only for three molecules was there some certainty. BDNF in plasma or serum does not reflect brain content, whereas free tryptophan (in plasma) and translocator protein (in blood cells) can serve as peripheral biomarkers. We expect a breakthrough in the field with advanced in vivo metabolomic analyses, neuroimaging techniques, and blood assays for exosomes of brain origin.

Verified
Journal Article
Open access
PDF file
Maria A TikhonovaMaria A Tikhonova
Maria A Tikhonova
ASAnna A. Shvaikovskaya
Anna A. Shvaikovskaya
SZSvetlana Ya Zhanaeva
Svetlana Ya Zhanaeva
GMGalina I. Moysak
Galina I. Moysak
AAAnna A. Akopyan
Anna A. Akopyan
LALyubomir I. Aftanas
Lyubomir I. Aftanas
The identification of reliable brain-specific biomarkers in periphery contributes to better understanding of normal neurophysiology and neuropsychiatric diseases. The neurospecific proteins BDNF, NSE, VILIP-1, and S100B play an important role in the pathogenesis of neuropsychiatric disorders, including epilepsy. This study aimed to assess the correspondence of the expression of BDNF, NSE, VILIP-1, and S100B in the blood (serum and peripheral blood mononuclear cells (PBMCs)) to the in vivo hippocampal levels of subjects with drug-resistant epilepsy who underwent neurosurgery (N = 44) using multiplex solid-phase analysis, ELISA, and immunohistochemical methods, as well as to analyze the correlations and associations of the blood and hippocampal levels of these proteins with clinical parameters. We first studied the concordance between in vivo brain and blood levels of BDNF, NSE, VILIP-1, and S100B in epileptic patients. A positive correlation for NSE between hippocampal and PBMC levels was revealed. NSE levels in PBMCs were also significantly correlated with average seizure duration. BDNF levels in PBMCs were associated with seizure frequency and hippocampal sclerosis. Thus, NSE and BDNF levels in PBMCs may have potential as clinically significant biomarkers. Significant correlations between the levels of the neurospecific proteins studied herein suggest interactions between BDNF, NSE, VILIP-1, and S100B in the pathophysiology of epilepsy.

10 March 2023
Verified
Book Chapter
Closed access
PDF file
EAElizaveta Alperina
Elizaveta Alperina
GIGalina Idova
Galina Idova
SZSvetlana Ya Zhanaeva
Svetlana Ya Zhanaeva

30 September 2020 in Сибирский вестник психиатрии и наркологии
Verified
Journal Article
Closed access
SZSvetlana Ya Zhanaeva
Svetlana Ya Zhanaeva
ЕАЕ.л. Альперина
Е.л. Альперина
МГМ.м. Геворгян
М.м. Геворгян
СДС.с. Дземидович
С.с. Дземидович
ГИГ.в. Идова
Г.в. Идова

1 March 2025 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
GIGalina V. Idova
Galina V. Idova
SZSvetlana Ya Zhanaeva
Svetlana Ya Zhanaeva
EAElizaveta L. Alperina
Elizaveta L. Alperina
SDSergei S. Dzemidovich
Sergei S. Dzemidovich
MGMargarita M. Gevorgyan
Margarita M. Gevorgyan
LALyubomir I. Aftanas
Lyubomir I. Aftanas
According to the modern concepts, neuroinflammation and peripheral immune dysfunction play key roles in the onset and progression of Parkinson’s disease (PD), one of the most common and severe neurodegenerative diseases. However, changes in the cellular and molecular immune parameters during the development of PD are still poorly understood. This work is devoted to analysis of the immune cell populations (monocytes, T- and B-cells and their subtypes), expression of Toll-like receptors (TLR), and spontaneous and mitogen-induced production of pro- and anti-inflammatory cytokines in the peripheral blood of the patients at different stages of idiopathic PD and healthy individuals. It was shown that the stage II of PD is characterized by the decrease in amount of the CD3+ T-cells, increase in the TLR2 expression on CD4+CD25+ Tregs, as well as increase in the spontaneous production of proinflammatory cytokines IFNγ and IL-17A. The stage III of PD is associated with the decrease in production of mitogen-induced IFNγ. Relative number of the CD19+CD25+ Breg cells in the patients with PD increased regardless of the disease stage. Thus, the obtained results indicate differences in the cellular and molecular immune parameters in the patients with PD and in the healthy individuals, which are dependent on the stage of the disease. These data are important for understanding molecular basis of PD development and prognosis of its course, and may be useful in identifying biomarkers of the disease severity and developing new treatment approaches depending on the stage of the disease.

30 December 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
SZSvetlana Ya Zhanaeva
Svetlana Ya Zhanaeva
Konstantin V. DanilenkoKonstantin V. Danilenko
Konstantin V. Danilenko
LALyubomir Aftanas
Lyubomir Aftanas